TScan Therapeutics (TCRX) EBIT Margin (2020 - 2025)
TScan Therapeutics (TCRX) has disclosed EBIT Margin for 6 consecutive years, with 929.41% as the latest value for Q4 2025.
- On a quarterly basis, EBIT Margin rose 459119.0% to 929.41% in Q4 2025 year-over-year; TTM through Dec 2025 was 1253.68%, a 353400.0% increase, with the full-year FY2025 number at 1315.38%, up 347230.0% from a year prior.
- EBIT Margin was 929.41% for Q4 2025 at TScan Therapeutics, up from 1669.74% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 296.17% in Q4 2023 to a low of 6364.55% in Q2 2024.
- A 5-year average of 1620.57% and a median of 619.62% in 2022 define the central range for EBIT Margin.
- Peak YoY movement for EBIT Margin: tumbled -558279bps in 2024, then surged 459119bps in 2025.
- TScan Therapeutics' EBIT Margin stood at 497.62% in 2021, then dropped by -21bps to 602.55% in 2022, then soared by 51bps to 296.17% in 2023, then tumbled by -1764bps to 5520.6% in 2024, then skyrocketed by 83bps to 929.41% in 2025.
- Per Business Quant, the three most recent readings for TCRX's EBIT Margin are 929.41% (Q4 2025), 1669.74% (Q1 2025), and 5520.6% (Q4 2024).